We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-15.61%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.41B
AUM Growth
-$2.89B
Cap. Flow
-$1.47B
Cap. Flow %
-27.24%
Top 10 Hldgs %
37.29%
Holding
165
New
19
Increased
15
Reduced
46
Closed
34

Top Buys

Rank Stock Value
1
LOGC
LogicBio Therapeutics, Inc. Common Stock
LOGC
+$78.1M
2
THOR
Synthorx, Inc. Common Stock
THOR
+$77.1M
3
CVS icon
CVS Health
CVS
+$59.3M
4
CELG
Celgene Corp
CELG
+$58.5M
5
GH icon
Guardant Health
GH
+$56.5M

Top Sells

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$149M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$98.5M
3
BMY icon
Bristol-Myers Squibb
BMY
+$81.7M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$81M
5
EW icon
Edwards Lifesciences
EW
+$79.7M

Sector Composition

Rank Sector Weight
1 Healthcare 95.11%
2 Financials 0.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XRAY icon
151
Dentsply Sirona
XRAY
$2.77B
– –
-1,889,200
Closed -$71.3M
PVLA
152
Palvella Therapeutics
PVLA
$2.03B
– –
-30,699
Closed -$13.8M
NVRO
153
DELISTED
NEVRO CORP.
NVRO
– –
-1,357,691
Closed -$77.4M
IMGN
154
DELISTED
Immunogen Inc
IMGN
– –
-1,469,189
Closed -$13.9M
GBT
155
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-309,500
Closed -$11.8M
RDUS
156
DELISTED
Radius Health, Inc.
RDUS
– –
-762,900
Closed -$13.6M
ADMS
157
DELISTED
Adamas Pharmaceuticals
ADMS
– –
-100,000
Closed -$1.3M
GWPH
158
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-21,000
Closed -$3.63M
ARRY
159
DELISTED
Array Biopharma Inc
ARRY
– –
-4,806,900
Closed -$73.1M
INSY
160
DELISTED
Insys Therapeutics, Inc.
INSY
– –
-3,028,354
Closed -$30.5M
LOXO
161
DELISTED
Loxo Oncology, Inc
LOXO
– –
-330,000
Closed -$56.4M
TSRO
162
DELISTED
TESARO, Inc.
TSRO
– –
-67,281
Closed -$2.63M
AET
163
DELISTED
Aetna Inc
AET
– –
-98,200
Closed -$19.9M
3 4 5 6
7

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q4 2018 Portfolio in Review

As of Q4 2018, OrbiMed held 165 positions worth $5.41B, down 35% from $8.3B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

OrbiMed withdrew a net $1.47B in Q4 2018, closing 34 positions and reducing 46 holdings. Its most notable exit was Jazz Pharmaceuticals, an estimated $149M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Financials.

Against the trend, OrbiMed opened a new position in LogicBio Therapeutics, Inc. Common Stock worth $67.3M.

  • OrbiMed's largest Q4 2018 buy was LogicBio Therapeutics, Inc. Common Stock: 6,466,783 shares worth $67.3M.
  • OrbiMed added most to Celgene Corp in Q4 2018, an estimated $58.5M increase.
  • OrbiMed's biggest Q4 2018 reduction was Alexion Pharmaceuticals, cutting an estimated $98.5M.
  • OrbiMed fully exited Jazz Pharmaceuticals in Q4 2018, selling an estimated $149M.
  • OrbiMed's ten largest holdings make up 37% of its $5.41B portfolio in Q4 2018.
  • OrbiMed opened 19 new positions and closed 34 in Q4 2018.
  • OrbiMed's portfolio value fell 35% quarter-over-quarter to $5.41B.

Based on OrbiMed's 13F filing for Q4 2018, filed 14 Feb 2019.